Seeking Alpha

Sorrento secures NIH grants

  • NIH division The National Institute of Allergy and Infectious Diseases ((NIAID) awards a Phase 2 Small Business Technology Transfer Research (STTR) grant to Sorrento Therapeutics (SRNE -0.6%). The funds available under the grant are up to $1M per year for two years. The money will support the advanced preclinical development of human bispecific antibody therapeutics to prevent and treat Staphylococcus aureus infections, including methicillin-resistant S. aureus.
  • NIAID also awards the company a Phase 1 STTR grant of $300K per year for up to two years to support the preclinical development of novel anti-Pseudomonas aeruginosa mAb immunotherapy or an Ab-mediated targeted antibiotic delivery vehicle.
  • Sorrento President & CEO Henry Ji, Ph.D., says, "While Sorrento's main focus is bringing the clinical stage oncology asset Cynviloq and resiniferatoxin into the market as quickly as possible, non-dilutive funding from the NIH allows us to explore innovative therapies for unmet medical needs such as multiple drug resistant bacterial infections."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|